Cardiovascular Risk in Prostate Cancer
Open Access
- 19 November 2024
- journal article
- research article
- Published by Elsevier in JACC: Cardiooncology
- Vol. 6 (6) , 835-846
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate CancerJAMA Oncology, 2024
- Survival in Patients With De Novo Metastatic Prostate CancerJAMA Network Open, 2024
- Invasive Treatment Strategy in Adults With Frailty and Non–ST-Segment Elevation Myocardial InfarctionJAMA Network Open, 2024
- Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet TherapyJAMA Network Open, 2023
- Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical ProstatectomyJAMA Network Open, 2023
- Cause of death during prostate cancer survivorship: A contemporary, US population–based analysisCancer, 2021
- Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate CancerJAMA Network Open, 2021
- Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparisonSupportive Care in Cancer, 2015
- Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate CancerJAMA, 2011
- Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancerCancer, 2008